Bristol-Myers Squibb Company (BMY)
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Can BMY's First CELMoD Approval Support Its Growth Strategy?
Bristol Myers wins FDA accelerated approval for Zenbexus, the first CELMoD therapy, as data show it doubles MRD-negative complete response rates.
Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines?
Bristol Myers growth portfolio now accounts for 56% of revenues, led by key drugs, including Opdivo Qvantig, Reblozyl and Breyanzi, helping offset generic erosion.
BMY Rallies 16.2% in Three Months: Buy, Sell or Hold the Stock?
Bristol Myers Squibb's Growth Portfolio and pipeline support momentum, but generic headwinds and recent gains call for a cautious stance.
Bristol Myers (BMY) Moves to Buy: Rationale Behind the Upgrade
Bristol Myers (BMY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BMY or AMGN: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Bristol Myers Squibb (BMY) and Amgen (AMGN). But which of these two stocks is more attractive to value investors?
Are Investors Undervaluing Bristol Myers Squibb (BMY) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Bristol Myers Squibb Company (BMY) Hit a 52 Week High, Can the Run Continue?
Bristol Myers (BMY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BMY Q2 Earnings Call Highlights Growth Portfolio Momentum
BMY highlights growth portfolio momentum, raises 2026 outlook and advances pipeline priorities as newer medicines drive results.
Bristol-Myers Squibb Company (BMY) Q2 2026 Earnings Call Transcript
Bristol-Myers Squibb Company (BMY) Q2 2026 Earnings Call Transcript
BMY Q2 Earnings Beat Estimates, '26 View Raised, Stock Up
Bristol Myers??? tops Q2 earnings and revenue estimates, raises 2026 guidance, and sees strong momentum from its Growth Portfolio and higher Eliquis demand.
